Unidose Liquid System Approved as First Nasal Rescue Treatment for Seizures

The FDA has approved the Unidose Liquid System (AptarGroup Inc) as the first and only nasal rescue treatment for acute repetitive seizures in patients with epilepsy.

The FDA has approved the Unidose Liquid System (AptarGroup Inc) as the first nasal rescue treatment for acute repetitive seizures in patients with epilepsy.1

The single-use, ready-to-use nasal delivery device can deliver a formulation in an emergency situation and is available to be administered by a non-health care professional to a patient during or after a seizure. The patient or caregiver is instructed to press a small plunger on the bottom of the device to release the drug in a single spray into the nostril, where the drug can be absorbed via the nasal mucosa.1

Noble International, recently acquired by Aptar, recently developed a trainer device in partnership with patients to be used as part of a patient onboarding program for this new device.1

According to the website, Unidose Liquid System is applicable for therapies where a small and very precise amount of active drug formulation is required in a single nasal shot.2

“When we combine our nasal systems’ capabilities with Noble’s training devices for onboarding, we bring added value to our customers and further convenience for patients and consumers worldwide," said Gael Touya, president of Aptar Pharma, in a prepared statement.”

REFERENCES

  • Aptar’s nasal unidose device approved by US FDA for first nasal rescue treatment for frequent seizure activity [news release]. Crystal Lake, Ill.; BusinessWire: December 9, 2019. https://www.businesswire.com/news/home/20191209005155/en/Aptar%E2%80%99s-Nasal-Unidose-Device-Approved-U.S.-FDA. Accessed December 9, 2019.
  • Single Shot Nasal Unidose Systems with Proven Performance. Aptar Pharma website. https://pharma.aptar.com/en-us/dispensing-solutions/uds.html. Accessed December 9, 2019.